Drugmaker Bristol Myers Squibb and private equity firm Bain Capital will launch an independent company focused on developing ...

Bristol Myers partners with Bain Capital to launch a new autoimmune-focused biotech, out-licensing five key immunology assets ...

Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives, Dan Lynch, and ...

Bristol Myers Squibb is spinning off a fresh company armed with five autoimmune disease drugs and $300 million in Bain ...

The newly formed biotech launches with five promising autoimmune candidates, $300 million in funding, and leadership from ...

Bristol Myers Squibb and Bain Capital launch a new biopharma firm focused on autoimmune disease treatments, starting with 5 ...

Backed by Bain Capital LP, the company has invited investment banks to pitch for roles in arranging the share sale, the ...

US pharma major Bristol Myers Squibb and Bain Capital announced the creation of a new independent biopharmaceutical company ...

The biopharma spinoff will advance the development of its five investigational therapies designed to treat autoimmune disease.

Bain Capital’s exit leaves Perpetual negotiating with Oaktree-backed financial planner roll-up AZ Next Generation Advisory.

HS Hyosung Advanced Materials has selected Bain Capital as the preferred bidder for its tire steel cord business unit. According to the investment banking (IB) industry on the 28th, HS Hyosung ...

Bain Capital is on the cusp of signing a deal to buy UK broker Jensten from private equity (PE) firm Livingbridge, Insurance ...